Evidence map›Paper›PMID 38277356›Full record

ArticlePloS one2024

Effect of an NHE3 inhibitor in combination with an NPT2b inhibitor on gastrointestinal phosphate absorption in Rodent models.

Xiaojun Wang, Xiaohong Yu, Kostas Gavardinas, Asim Dey, Hong Y Zhang, Gina Porter, Leah Porras, Lan Yu, Haihong Guo, Charles A Reidy and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. New functions and roles of the NaPflugers Archiv : European journal of physiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Xiaojun WangLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.ORCID 0000-0002-6802-2623
Xiaohong YuLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Kostas GavardinasLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Asim DeyLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Hong Y ZhangLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Gina PorterLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Leah PorrasLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Lan YuLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Haihong GuoLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Charles A ReidyLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Joseph V HaasLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Yanping XuLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Mark C KowalaLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Prabhakar K JadhavLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
John R WetterauLilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.
Eli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many of the pathological consequences of chronic kidney disease can be attributed to an elevation in serum phosphate levels. Current therapies focused on decreasing intestinal phosphate absorption to treat hyperphosphatemia are inadequate. The most effective therapeutic strategy may be to target multiple absorptive pathways. In this study, the ability of a novel inhibitor of the intestinal sodium hydrogen exchanger 3 (NHE3), LY3304000, which inhibits paracellular, diffusional uptake of phosphate, to work in combination with an inhibitor of the active transporter, sodium dependent phosphate cotransporter 2b (NPT2b), LY3358966, was explored. LY3304000 modestly inhibited the acute uptake of phosphate into plasma of rats, while surprisingly, it doubled the rate of phosphate uptake in mice, an animal model dominated by NPT2b mediated acute phosphate uptake. In rats, LY3004000 and LY3358966 work in concert to inhibit acute phosphate uptake. On top of LY3358966, LY3304000 further decreased the acute uptake of phosphate into plasma. Studies measuring the recovery of radiolabeled phosphate in the intestine demonstrated LY3304000 and LY3358966 synergistically inhibited the absorption of phosphate in rats. We hypothesize the synergism is because the NHE3 inhibitor, LY3304000, has two opposing effects on intestinal phosphate absorption in rats, first it decreases diffusion mediated paracellular phosphate absorption, while second, it simultaneously increases phosphate absorption through the NPT2b pathway. NHE3 inhibition decreases proton export from enterocytes and raises the cell surface pH. In vitro, NPT2b mediated phosphate transport is increased at higher pHs. The increased NPT2b mediated transport induced by NHE3 inhibition is masked in rats which have relatively low levels of NPT2b mediated phosphate transport, by the more robust inhibition of diffusion mediated phosphate absorption. Thus, the inhibition of NPT2b mediated phosphate transport in rats in the presence of NHE3 inhibition has an effect that exceeds its effect in the absence of NHE3 inhibition, leading to the observed synergism on phosphate absorption between NPT2b and NHE3 inhibition.

Indexed as

PhosphatesRenal Insufficiency, ChronicAnimalsIntestinal AbsorptionMiceRatsRodentiaSodium-Hydrogen Exchanger 3Sodium-Hydrogen ExchangersPhosphatesSodium-Hydrogen Exchanger 3Sodium-Hydrogen Exchangers

Identifiers

PMID38277356
PMCPMC10817170
OpenAlexW4391263048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.